Gelteq (GELS) Competitors $1.68 +0.02 (+1.49%) As of 08/6/2025 03:08 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock GELS vs. QNTM, FBRX, MNOV, IRD, RPTX, INMB, INKT, BMEA, IZTC, and APLTShould you be buying Gelteq stock or one of its competitors? The main competitors of Gelteq include Quantum Biopharma (QNTM), Forte Biosciences (FBRX), MediciNova (MNOV), Opus Genetics (IRD), Repare Therapeutics (RPTX), INmune Bio (INMB), MiNK Therapeutics (INKT), Biomea Fusion (BMEA), Invizyne Technologies (IZTC), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical products" industry. Gelteq vs. Its Competitors Quantum Biopharma Forte Biosciences MediciNova Opus Genetics Repare Therapeutics INmune Bio MiNK Therapeutics Biomea Fusion Invizyne Technologies Applied Therapeutics Gelteq (NASDAQ:GELS) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation. Does the media favor GELS or QNTM? In the previous week, Quantum Biopharma had 5 more articles in the media than Gelteq. MarketBeat recorded 5 mentions for Quantum Biopharma and 0 mentions for Gelteq. Gelteq's average media sentiment score of 0.00 equaled Quantum Biopharma'saverage media sentiment score. Company Overall Sentiment Gelteq Neutral Quantum Biopharma Neutral Is GELS or QNTM more profitable? Gelteq's return on equity of 0.00% beat Quantum Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets GelteqN/A N/A N/A Quantum Biopharma N/A -155.20%-94.90% Do insiders & institutionals hold more shares of GELS or QNTM? 1.2% of Quantum Biopharma shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has preferable earnings and valuation, GELS or QNTM? Gelteq has higher revenue and earnings than Quantum Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGelteq$100K159.04-$2.33MN/AN/AQuantum BiopharmaN/AN/A-$14.20M-$15.98-1.64 SummaryGelteq beats Quantum Biopharma on 4 of the 7 factors compared between the two stocks. Get Gelteq News Delivered to You Automatically Sign up to receive the latest news and ratings for GELS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GELS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GELS vs. The Competition Export to ExcelMetricGelteqMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.67M$3.01B$5.57B$9.47BDividend YieldN/A2.41%4.31%4.13%P/E RatioN/A16.5729.3723.99Price / Sales159.04314.79444.1896.63Price / CashN/A42.1735.8458.51Price / Book1.307.818.085.58Net Income-$2.33M-$54.52M$3.26B$265.35M7 Day Performance-2.62%0.41%0.45%-0.07%1 Month Performance0.88%9.93%4.83%1.76%1 Year PerformanceN/A15.18%30.28%25.39% Gelteq Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GELSGelteqN/A$1.68+1.5%N/AN/A$15.67M$100K0.00N/AQNTMQuantum BiopharmaN/A$23.12+1.8%N/AN/A$67.28MN/A-1.45N/ANews CoverageEarnings ReportUpcoming EarningsGap UpFBRXForte Biosciences3.1406 of 5 stars$10.15-0.4%$61.00+501.0%+56,708.4%$66.69MN/A-0.625News CoverageUpcoming EarningsOptions VolumeMNOVMediciNova2.7098 of 5 stars$1.35-0.4%$7.00+420.4%+14.3%$65.97M$1M-5.8510IRDOpus Genetics1.315 of 5 stars$1.11+1.4%$7.33+563.7%N/A$65.93M$13.65M-0.5314News CoverageUpcoming EarningsGap UpRPTXRepare Therapeutics2.7614 of 5 stars$1.52+0.7%$4.50+196.1%-52.6%$65.19M$53.48M-0.50180INMBINmune Bio2.3605 of 5 stars$2.78+3.7%$18.40+561.9%-61.5%$64.96M$10K-1.4310Positive NewsGap UpINKTMiNK Therapeutics2.4331 of 5 stars$16.25-1.8%$37.50+130.8%+54.0%$64.50MN/A-6.4130Upcoming EarningsBMEABiomea Fusion3.7152 of 5 stars$1.69+1.6%$20.10+1,092.2%-73.9%$63.68MN/A-0.4850News CoverageEarnings ReportAnalyst ForecastIZTCInvizyne TechnologiesN/A$9.98+0.3%N/AN/A$62.40MN/A0.0029Positive NewsGap UpAPLTApplied Therapeutics4.0917 of 5 stars$0.44+1.1%$6.10+1,302.3%-92.7%$61.59M$460K-1.0130 Related Companies and Tools Related Companies Quantum Biopharma Competitors Forte Biosciences Competitors MediciNova Competitors Opus Genetics Competitors Repare Therapeutics Competitors INmune Bio Competitors MiNK Therapeutics Competitors Biomea Fusion Competitors Invizyne Technologies Competitors Applied Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GELS) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelteq Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelteq With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
